Bristol Myers Squibb News

Eli Lilly and Company is heading straight for a patent cliff. Zyprexa lost patent protection in most major markets in 2011.

BMY has experienced a decrease in support from the world's most elite money managers recently.

On the morning of Aug. 18, 2004, Dinesh Thakur hurried to a hastily arranged meeting with his boss at the gleaming offices of Ranbaxy Laboratories in Gurgaon, India, 20 miles south of New Delhi.

The annual conference of The American Society of Clinical Oncology is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is the buzz word for this year's conference.

A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.

WASHINGTON, May 23, 2013 The mood is grim on Wall Street this morning after yesterday's double whammy.

As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Top US stock recommendations of the day: ADVANCED MICRO DEVICES: Jefferies & Co reiterates BUY rating.

Pharmaceutical names dominated the S&P 500's leaderboard with Bristol-Myers Squibb Co.

A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In what is apparently an unusual move, the US Department of Agriculture earlier this year fined Bristol-Myers Squibb for violating the Animal Welfare Act after the deaths of two monkeys in its laboratories.

Teva Pharmaceutical Industries Ltd., which just two years ago was analysts' highest-rated stock among the world's 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.

's stock had its "buy" rating restated by equities researchers at Investec in a report issued on Tuesday, StocKRatingsNetwork.com reports.

Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.

Royal Bank of Scotland was in the lead after Numis raised its target price from 308p to 410p, while upgrading the stock to buy.

Zhejiang Hisun Pharmaceutical Co's pavilion at a fair in Beijing. By setting up a joint venture with US-based Pfizer Inc in September, Hisun made a breakthrough in China's pharmaceutical industry by taking a controlling stake in the JV with Pfizer, the world's largest drug-maker by sales.

Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.

Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.

Bristol-Myers shares were up 5.1 percent at $44.35 shortly before the close on Wednesday, in their busiest day of trading since August.

Bristol-Myers Squibb's Joseph Campisi and Demetrios Kyonieus were virtually inseparable for eight months in 2012 while they negotiated an M&A deal that was large and complex.